Patent US3969502A successfully refreshed from Google Patents.
US3969502A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for contraception by the administration of sequential contraceptive preparations
Assignee: Bayer Pharma AG
•
Filing: 1974-07-09
•
Granted: 1976-07-13
•
Expires: 1994-07-09
Abstract
Abstract Method of contraception over a 21-day cycle in which an estrogen and a progestogen are administered in a low dosage for 10-12 days and thereafter at a slightly higher dosage for the next 11-9 days.
Inventors
- 👤 Ursula Lachnit-Fixson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 16:01
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K31/565
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
113 words
A method of contraception wherein a combination of an estrogen and a progestogen is administered orally to a female of child-bearing age for about 21 days and for the next 5-7 days, for a total of about 28 days, no estrogens and progestogens are administered, which comprises administering orally daily for the first 10-12 days either a combination of: a. 0.030 mg. of 17α-ethinylestradiol and 0.050 mg. of d-norgestrel, or a combination of: b. 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortestosterone acetate; and then administering orally daily for the next 11-9 days, when combination (a) is administered for the first 10-12 days, a combination of c. 0.040 mg. of 17α-ethinylestradiol and
Claim 2
Independent Claim
113 words
A method of contraception wherein a combination of an estrogen and a progestogen is administered orally to a female of child-bearing age for about 21 days and for the next 5-7 days, for a total of about 28 days, no estrogens and progestogens are administered, which comprises administering orally daily for the first 10-12 days either a combination of: a. 0.030 mg. of 17α-ethinylestradiol and 0.050 mg. of d-norgestrel, or a combination of: b. 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortestosterone acetate; and then administering orally daily for the next 11-9 days, when combination (a) is administered for the first 10-12 days, a combination of c. 0.040 mg. of 17α-ethinylestradiol and
Claim 3
Dependent Claim
42 words
125 mg. of d-norgestrel, or when combination (b) is administered for the first 10-12 days, a combination either of: d. 0.050 mg. of 17α-ethinylestradiol and 2 mg. of 17-ethinyl-19-nortestosterone acetate; or e. 0.050 mg. of 17-ethinylestradiol and 2 mg. of cyproterone acetate.
Claim 4
Dependent Claim
42 words
125 mg. of d-norgestrel, or when combination (b) is administered for the first 10-12 days, a combination either of: d. 0.050 mg. of 17α-ethinylestradiol and 2 mg. of 17-ethinyl-19-nortestosterone acetate; or e. 0.050 mg. of 17-ethinylestradiol and 2 mg. of cyproterone acetate.
Claim 5
Dependent Claim
44 words
A method according to claim 1 wherein for the first 10-12 days 0.030 mg. of 17α-ethinylestradiol and 0.050 mg. of d-norgestrel are administered daily and for the next 11-9 days 0.040 days 0.040 mg. of 17-ethinylestradiol and 0.125 mg. of d-norgestrel are administered daily.
Claim 6
Independent Claim
43 words
A method according to 1 wherein for the first 10-12 days 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortestosterone acetate is administered daily and for the next 11-9 days 0.050 mg. of 17α-ethinylestradiol and 2 mg. of 17α-ethinyl-19-nortestosterone acetate are administered daily.
Claim 7
Independent Claim
43 words
A method according to 1 wherein for the first 10-12 days 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortestosterone acetate is administered daily and for the next 11-9 days 0.050 mg. of 17α-ethinylestradiol and 2 mg. of 17α-ethinyl-19-nortestosterone acetate are administered daily.
Claim 8
Dependent Claim
44 words
A method according to claim 1 wherein for the first 10-12 days 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortestosterone acetate is administered daily and for the next 11-9 days 0.050 mg. of 17α-ethinylestradiol and 2 mg. of cyproterone acetate are administered daily.
Claim 9
Dependent Claim
124 words
A two-stage combination oral contraceptive composition comprising about 21 daily doses of a contraceptively effective combination of an estrogen a progestogen consisting essentially of, in a first stage of 10-12 successive units, a combination of: a. 0.030 mg. of 17α-ethinylestradiol and 0.050 mg. of d-norgestrel, or a combination of b. 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortesterone acetate; and, in a second stage of 11-9 successive units, a combination, when the first stage is combination (a), of c. 0.040 mg. of 17α-ethinylestradiol and 0.125 mg. of d-norgestrel or a combination, when the first state is combination (b), either of: d. 0.050 mg. of 17α-ethinylestradiol and 2 mg. of 17-ethinyl-19-nortestosterone acetate; or e. 0.050 mg. of 17-ethinylestradiol and 2 mg. of cyproterone acetate.
Claim 10
Dependent Claim
124 words
A two-stage combination oral contraceptive composition comprising about 21 daily doses of a contraceptively effective combination of an estrogen a progestogen consisting essentially of, in a first stage of 10-12 successive units, a combination of: a. 0.030 mg. of 17α-ethinylestradiol and 0.050 mg. of d-norgestrel, or a combination of b. 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortesterone acetate; and, in a second stage of 11-9 successive units, a combination, when the first stage is combination (a), of c. 0.040 mg. of 17α-ethinylestradiol and 0.125 mg. of d-norgestrel or a combination, when the first state is combination (b), either of: d. 0.050 mg. of 17α-ethinylestradiol and 2 mg. of 17-ethinyl-19-nortestosterone acetate; or e. 0.050 mg. of 17-ethinylestradiol and 2 mg. of cyproterone acetate.
Claim 11
Dependent Claim
16 words
A contraceptive composition according to claim 5 wherein the estrogen and progestogen are in tablet form.
Claim 12
Dependent Claim
47 words
A contraceptive composition according to claim 5 wherein in the first stage, the estrogen is 0.030 mg. of 17α-ethinylestradiol and the progestogen is 0.050 mg. of d-norgestrel per unit dosage and, in the second state, 0.040 mg. of 17α-ethinylestradiol and 0.125 mg. of d-norgestrel per unit dosage.
Claim 13
Dependent Claim
49 words
A contraceptive composition according to claim 5 wherein, in the first stage, the estrogen is 0.030 mg. of 17α-ethinylestradiol and the progestogen is 1 mg. of 17α-ethinyl-19-nortestosterone acetate per unit dosage and, in the second stage, 0.050 mg. of 17α-ethinylestradiol and 2 mg. of 17α-ethinyl-19-nortestosterone acetate per unit dosage.
Claim 14
Dependent Claim
43 words
A contraceptive composition according to claim 5 containing, in the first stage 0.030 mg. of 17α-ethinylestradiol and 1 mg. of 17α-ethinyl-19-nortestosterone acetate per unit dosage and, in the second stage, 0.050 mg. of 17α-ethinylestradiol and 2 mg. of cyproterone acetate per unit dosage.
References Cited (Backward Citations)
US3568828A
Cited
US3409721A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-07-13 | 1980-01-12 | 1980-07-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-07-13 | 1984-01-12 | 1984-07-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-07-13 | 1988-01-12 | 1988-07-13 | $7700.00 | Window Closed / Lapsed |